Decoding disease

Glycan sequencingpowered by AI-designed
molecular detectors

We’re developing SynLecs, synthetic lectins that recognize glycan features, to open new possibilities in diagnostics and biological research.

Oxum scientists developing glycan sequencing technology in the lab
01

Oxum Glycosciences
Make glycan structure measurable.

01 The opportunity

Disease changes glycans.We detect the difference.

Glycans are branched chains of sugars. Their structures change in cancer, autoimmune disease, and infection. Reading those changes could reveal a broader class of diagnostic signals.

Experimentally determined human IgG1 Fc structure with attached glycans, PDB 5JII
ProteinGlycansHuman IgG1 Fc · PDB 5JII · X-ray structure ↗
AI-guided SynLec design feeds into a repeating cycle: test binding and selectivity, select promising binders, and adapt through AI-guided refinement.
02 Our approach

Meet SynLecs,
our molecular detectors

SynLecs are synthetic lectins: proteins we’re engineering to recognize specific glycan structures. They provide the molecular recognition that enables our sequencing platform.

03 Supporters

Investors & strategic partners.

Investors

Y Combinator
Insi
Sunshine Lake
Bluegrass Ventures
Browder Capital

Partner

Hyde Park Labs
04 Our Founders

From Nobel Labs to Next-Gen Diagnostics

Arthur Costa, CEO at Oxum GlycosciencesCEO

Arthur Costa

BS Chemical Biology, UChicago ’27

Chemical biology research in the labs of Nobel laureates Jennifer Doudna and Jack Szostak. 2026 Goldwater Scholar.

Michael Bolgov, CTO at Oxum GlycosciencesCTO

Michael Bolgov

BS Molecular Engineering, UChicago ’27

Biomolecular engineering research in Nobel laureate Jack Szostak’s lab, with experience across startups and industry. Previously on Jane Street’s strategy and product team.

Nora Levy, COO at Oxum GlycosciencesCOO

Nora Levy

BA/MA Economics, UChicago ’27

Management, grant writing, and fundraising experience, with direct experience supporting founder Josh Penn.

05 Contact

Making glycan sequencing
a reality

Talk with us about research, investment, or building the next generation of glycan sequencing tools.

contact@oxumglyco.com